» Articles » PMID: 15610259

Clinical and Pathologic Characteristics of Dilated Cardiomyopathy in Hemodialysis Patients

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2004 Dec 22
PMID 15610259
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Some dialysis patients have impaired left ventricular (LV) function without coronary artery disease. The pathologic changes and prognoses of these patients have not been well described.

Methods: We performed LV endomyocardial biopsies on 40 hemodialysis patients with dilated cardiomyopathy (DCM; an ejection fraction <50% and a left ventricular end-diastolic volume index >90 mL/m(2) without coronary artery disease), and on 50 nondialysis patients with idiopathic DCM as the control group. Following LV biopsies, the patients were followed-up for a mean of 3.1 +/- 2.3 years.

Results: The pathologic characteristics of the dialysis group were severe myocyte hypertrophy (the mean myocyte diameter across the nucleus: 37.6 +/- 10.5 mum vs. 25.6 +/- 7.7 mum, P= 0.001), myocyte disarray (30%), and extensive fibrosis (the mean percent area of left ventricular fibrosis: 22.3 +/- 18.4% vs. 21.3 +/- 14.6%, P= NS). These pathologic characteristics resembled the dilated phase of hypertrophic cardiomyopathy. In the dialysis group, a high percent area of LV fibrosis was the only significant predictor of cardiac death by multivariate analysis (P= 0.02). The 3-year cumulative event-free survival rate for cardiac death in dialysis patients with severe fibrosis (more than 30%) was 42%, while that for patients without severe fibrosis was 82% (P= 0.03).

Conclusion: The pathologic characteristics of the heart in dialysis patients with DCM are interstitial fibrosis and severe myocyte hypertrophy with occasional disarray. The extent of LV fibrosis is a strong predictor of cardiac death. Careful follow-up and treatment are necessary for dialysis patients with a high percent area of LV fibrosis.

Citing Articles

Myocardial involvement in end-stage renal disease patients with anemia as assessed by cardiovascular magnetic resonance native T1 mapping: An observational study.

Chen L, Xu R, Xu H, Yang Z, Zhang Y, Li Z Medicine (Baltimore). 2024; 103(46):e39724.

PMID: 39560547 PMC: 11575988. DOI: 10.1097/MD.0000000000039724.


Cardiac Magnetic Resonance Imaging Findings in Patients With Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.

Chandramohan D, Rajasekaran R, Konda R, Pujari A, Avula S, Bell M Cureus. 2024; 16(1):e51672.

PMID: 38313918 PMC: 10838180. DOI: 10.7759/cureus.51672.


C-terminal fragment of fibroblast growth factor 23 improves heart function in murine models of high intact fibroblast growth factor 23.

Hu M, Reneau J, Shi M, Takahashi M, Chen G, Mohammadi M Am J Physiol Renal Physiol. 2024; 326(4):F584-F599.

PMID: 38299214 PMC: 11208029. DOI: 10.1152/ajprenal.00298.2023.


Chronic kidney disease associated cardiomyopathy: recent advances and future perspectives.

Dobre M, Ahlawat S, Schelling J Curr Opin Nephrol Hypertens. 2024; 33(2):203-211.

PMID: 38193308 PMC: 10872957. DOI: 10.1097/MNH.0000000000000952.


Echocardiographic manifestations in end-stage renal disease.

Ito T, Akamatsu K Heart Fail Rev. 2023; 29(2):465-478.

PMID: 38071738 DOI: 10.1007/s10741-023-10376-5.